Details
Stereochemistry | ACHIRAL |
Molecular Formula | C9H9NO3.C6H12N4 |
Molecular Weight | 319.3589 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C1N2CN3CN1CN(C2)C3.OC(=O)CNC(=O)C4=CC=CC=C4
InChI
InChIKey=ROAIXOJGRFKICW-UHFFFAOYSA-N
InChI=1S/C9H9NO3.C6H12N4/c11-8(12)6-10-9(13)7-4-2-1-3-5-7;1-7-2-9-4-8(1)5-10(3-7)6-9/h1-5H,6H2,(H,10,13)(H,11,12);1-6H2
Molecular Formula | C6H12N4 |
Molecular Weight | 140.1863 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C9H9NO3 |
Molecular Weight | 179.1727 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/24689705Curator's Comment: description was created based on several sources, including, http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/016151s025lbl.pdf
Sources: http://www.ncbi.nlm.nih.gov/pubmed/24689705
Curator's Comment: description was created based on several sources, including, http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/016151s025lbl.pdf
Methenamine is an antibacterial agent for preventing recurrent urinary tract infection. It can be used as methenamine hippurate or methenamine mandelate preparations and is United States Food and Drug Administration-approved. Methenamine exerts its activity because it is hydrolyzed to formaldehyde in acid urine.
Originator
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | UREX Approved UseFOR URAMIT MB™: URAMIT MB™ is indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures. Launch Date1967 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
34 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7076604/ |
1 g 2 times / day multiple, oral dose: 1 g route of administration: Oral experiment type: MULTIPLE co-administered: |
METHENAMINE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
177 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7076604/ |
1 g 2 times / day multiple, oral dose: 1 g route of administration: Oral experiment type: MULTIPLE co-administered: |
METHENAMINE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7076604/ |
1 g 2 times / day multiple, oral dose: 1 g route of administration: Oral experiment type: MULTIPLE co-administered: |
METHENAMINE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
1 g 2 times / day multiple, oral Recommended Dose: 1 g, 2 times / day Route: oral Route: multiple Dose: 1 g, 2 times / day Sources: |
healthy, 24-65 n = 10 Health Status: healthy Age Group: 24-65 Sex: M+F Population Size: 10 Sources: |
|
1 g single, oral Recommended |
healthy, 24-65 n = 10 Health Status: healthy Age Group: 24-65 Sex: M+F Population Size: 10 Sources: |
|
8 g 1 times / day multiple, oral Overdose Dose: 8 g, 1 times / day Route: oral Route: multiple Dose: 8 g, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Urinary tract infections Sources: |
Other AEs: Bladder irritation, Micturition painful... Other AEs: Bladder irritation Sources: Micturition painful Micturition frequency Albuminuria Hematuria |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Albuminuria | 8 g 1 times / day multiple, oral Overdose Dose: 8 g, 1 times / day Route: oral Route: multiple Dose: 8 g, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Urinary tract infections Sources: |
|
Bladder irritation | 8 g 1 times / day multiple, oral Overdose Dose: 8 g, 1 times / day Route: oral Route: multiple Dose: 8 g, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Urinary tract infections Sources: |
|
Hematuria | 8 g 1 times / day multiple, oral Overdose Dose: 8 g, 1 times / day Route: oral Route: multiple Dose: 8 g, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Urinary tract infections Sources: |
|
Micturition frequency | 8 g 1 times / day multiple, oral Overdose Dose: 8 g, 1 times / day Route: oral Route: multiple Dose: 8 g, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Urinary tract infections Sources: |
|
Micturition painful | 8 g 1 times / day multiple, oral Overdose Dose: 8 g, 1 times / day Route: oral Route: multiple Dose: 8 g, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Urinary tract infections Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Simulated cometary matter as a test for enantiomer separating chromatography for use on comet 46P/Wirtanen. | 2001 |
|
The unpredictability of seal after post space preparation: a fluid transport study. | 2001 Apr |
|
Comparative effects of aging in men and women on the properties of the arterial tree. | 2001 Apr |
|
The lock-in phase in the urotropine-sebacic acid system. | 2001 Aug |
|
Developmental changes in the fine structure and histochemical properties of mucous cells in the parotid gland of the infant Japanese macaque. | 2001 Dec |
|
Evaluation of the genotoxicity of zinc oxide eugenol-based, calcium hydroxide-based, and epoxy resin-based root canal sealers by comet assay. | 2001 Dec |
|
Plaque-like structures and arteriosclerotic changes in "diffuse neurofibrillary tangles with calcification" (DNTC). | 2001 Dec |
|
The 143 and 300 K polymorphs of hexamethylenetetraminium 2,4-dinitrophenolate monohydrate. | 2001 Dec |
|
Septum formation in Aspergillus nidulans. | 2001 Dec |
|
Occupational allergic contact dermatitis from quaternium-15 in an electroencephalography skin preparation gel. | 2001 Jan |
|
Evidence for the binding of a human sperm component with diaphanous protein. | 2001 Jan-Feb |
|
Toward designed assembly of microporous coordination networks constructed from silver(I)-hexamethylenetetramine layers. | 2001 Jul 2 |
|
Formaldehyde release from ground root canal sealer in vitro. | 2001 Jun |
|
Cenani-Lenz syndrome with renal hypoplasia is not linked to FORMIN or GREMLIN. | 2001 Mar |
|
In vitro longitudinal assessment of coronal discoloration from endodontic sealers. | 2001 Nov |
|
Methenamine hippurate for preventing urinary tract infections. | 2002 |
|
The evolutionary history of effectors downstream of Cdc42 and Rac. | 2002 |
|
Comparison of staining methods and a nested PCR assay to detect Histoplasma capsulatum in tissue sections. | 2002 Apr |
|
Dipole-dipole coupling constant for a directly bonded CH pair--a carbon-13 relaxation study. | 2002 Aug |
|
Formins initiate new actin filaments. | 2002 Aug |
|
Dramatic rate acceleration of the Baylis-Hillman reaction in homogeneous medium in the presence of water. | 2002 Dec 26 |
|
Cytotoxicity of resin-, zinc oxide-eugenol-, and calcium hydroxide-based root canal sealers on human periodontal ligament cells and permanent V79 cells. | 2002 Feb |
|
A 1:1 adduct of hexamethylenetetramine and 4-hydroxy-3-methoxybenzaldehyde. | 2002 Jan |
|
A comparative evaluation of sealing ability of rootcanal sealers. | 2002 Jan-Mar |
|
Primary evaluation of methenamine as a NPN compound with probable effects on increasing ruminal escaped protein. | 2002 Jun |
|
Dimethylsilane polyamines: cytostatic compounds with potentials as anticancer drugs. II. Uptake and potential cytotoxic mechanisms. | 2002 Nov-Dec |
|
AgC(CN)3-based coordination polymers. | 2003 Apr 21 |
|
Syntheses of two new 1D and 3D networks of Cu(II) and Co(II) using malonate and urotropine as bridging ligands: crystal structures and magnetic studies. | 2003 Apr 21 |
|
(1R,3S)-Camphoric acid as a building block in supramolecular chemistry: adducts with organic polyamines. | 2003 Feb |
|
Salts of maleic and fumaric acids with organic polyamines: comparison of isomeric acids as building blocks in supramolecular chemistry. | 2003 Feb |
|
ForC, a novel type of formin family protein lacking an FH1 domain, is involved in multicellular development in Dictyostelium discoideum. | 2003 Feb 15 |
|
Crystallographic analysis of the thermal motion of the inclusion complex of cyclomaltoheptaose (beta-cyclodextrin) with hexamethylenetetramine. | 2003 Feb 7 |
|
Adducts of hexamethylenetetramine with ferrocenecarboxylic acid and ferrocene-1,1'-dicarboxylic acid: multiple disorder in space groups Fmm2 and Cmcm. | 2003 Jul |
|
Prognostic significance of microvascular thrombosis in donor kidney allograft biopsies. | 2003 Jun 15 |
|
Immunofluorescence of the epizootic ulcerative syndrome pathogen, Aphanomyces invadans, using a monoclonal antibody. | 2003 Jun 20 |
|
[Quantitative assessment of the biological activity of chemicals by soil microbial associations]. | 2003 May-Jun |
|
Activation of the Rac-binding partner FHOD1 induces actin stress fibers via a ROCK-dependent mechanism. | 2003 Oct 3 |
Patents
Sample Use Guides
One tablet (1 g) twice daily for adults and children over 12 years of age. One-half tablet or one tablet (0.5 or 1 g) twice daily for children 6 to 12 years of age.
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/7028634
The antibacterial activity of methenamine and two of its organic acid salts was compared by continuous turbidimetric monitoring of static cultures exposed to the drugs and in an in vitro model of the treatment of bacterial cystitis. At pH 5.5, concentrations of 32 to 125 mg methenamine per 1 caused some inhibition of bacterial growth (Klebsiella aerogenes), but 250 to 500 mg/l were needed to suppress growth overnight. Methenamine hippurate was found to be less active than methenamine itself, whereas methenamine mandelate was as active as the parent compound.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:11:36 GMT 2023
by
admin
on
Fri Dec 15 15:11:36 GMT 2023
|
Record UNII |
M329791L57
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C255
Created by
admin on Fri Dec 15 15:11:36 GMT 2023 , Edited by admin on Fri Dec 15 15:11:36 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB14537MIG
Created by
admin on Fri Dec 15 15:11:36 GMT 2023 , Edited by admin on Fri Dec 15 15:11:36 GMT 2023
|
PRIMARY | |||
|
5714-73-8
Created by
admin on Fri Dec 15 15:11:36 GMT 2023 , Edited by admin on Fri Dec 15 15:11:36 GMT 2023
|
PRIMARY | |||
|
21945
Created by
admin on Fri Dec 15 15:11:36 GMT 2023 , Edited by admin on Fri Dec 15 15:11:36 GMT 2023
|
PRIMARY | |||
|
DBSALT001270
Created by
admin on Fri Dec 15 15:11:36 GMT 2023 , Edited by admin on Fri Dec 15 15:11:36 GMT 2023
|
PRIMARY | |||
|
M329791L57
Created by
admin on Fri Dec 15 15:11:36 GMT 2023 , Edited by admin on Fri Dec 15 15:11:36 GMT 2023
|
PRIMARY | |||
|
DTXSID10972603
Created by
admin on Fri Dec 15 15:11:36 GMT 2023 , Edited by admin on Fri Dec 15 15:11:36 GMT 2023
|
PRIMARY | |||
|
CHEMBL1201270
Created by
admin on Fri Dec 15 15:11:36 GMT 2023 , Edited by admin on Fri Dec 15 15:11:36 GMT 2023
|
PRIMARY | |||
|
100000091093
Created by
admin on Fri Dec 15 15:11:36 GMT 2023 , Edited by admin on Fri Dec 15 15:11:36 GMT 2023
|
PRIMARY | |||
|
29652
Created by
admin on Fri Dec 15 15:11:36 GMT 2023 , Edited by admin on Fri Dec 15 15:11:36 GMT 2023
|
PRIMARY | RxNorm | ||
|
M329791L57
Created by
admin on Fri Dec 15 15:11:36 GMT 2023 , Edited by admin on Fri Dec 15 15:11:36 GMT 2023
|
PRIMARY | |||
|
C011481
Created by
admin on Fri Dec 15 15:11:36 GMT 2023 , Edited by admin on Fri Dec 15 15:11:36 GMT 2023
|
PRIMARY | |||
|
C47610
Created by
admin on Fri Dec 15 15:11:36 GMT 2023 , Edited by admin on Fri Dec 15 15:11:36 GMT 2023
|
PRIMARY | |||
|
1409502
Created by
admin on Fri Dec 15 15:11:36 GMT 2023 , Edited by admin on Fri Dec 15 15:11:36 GMT 2023
|
PRIMARY | |||
|
m7308
Created by
admin on Fri Dec 15 15:11:36 GMT 2023 , Edited by admin on Fri Dec 15 15:11:36 GMT 2023
|
PRIMARY | Merck Index | ||
|
Methenamine Hippurate
Created by
admin on Fri Dec 15 15:11:36 GMT 2023 , Edited by admin on Fri Dec 15 15:11:36 GMT 2023
|
PRIMARY | |||
|
227-206-5
Created by
admin on Fri Dec 15 15:11:36 GMT 2023 , Edited by admin on Fri Dec 15 15:11:36 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |